Journal: Vaccines

Article Title: Randomized Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of V114, a 15-Valent PCV, Followed by PPSV23 6 Months Later (PNEU-DAY): Subgroup Analysis in Adults 18–49 Years of Age Enrolled at Center for Indigenous Health Sites

doi: 10.3390/vaccines14010003

Figure Lengend Snippet: Participant flow chart. Data are for participants enrolled at Center for Indigenous Health sites. The denominator for calculations is based on the number randomized. The “completed trial” classification may include participants who missed PPSV23 administration. Abbreviations: PCV13, 13-valent pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal polysaccharide vaccine; V114, 15-valent pneumococcal conjugate vaccine.

Article Snippet: V114 (VAXNEUVANCETM, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA [MSD]) is a 15-valent PCV that contains the 13 serotypes in PCV13 plus two epidemiologically important serotypes (22F and 33F) that cause IPD [ , , , , , , , ].

Techniques:

Journal: Vaccines

Article Title: Randomized Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of V114, a 15-Valent PCV, Followed by PPSV23 6 Months Later (PNEU-DAY): Subgroup Analysis in Adults 18–49 Years of Age Enrolled at Center for Indigenous Health Sites

doi: 10.3390/vaccines14010003

Figure Lengend Snippet: Post-vaccination solicited AEs, by study group. Data are for participants enrolled at Center for Indigenous Health sites. Injection-site events were solicited from Days 1–5 following vaccination. Systemic events were solicited from Days 1–14 following vaccination. a For solicited injection-site swelling and injection-site erythema, mild events measured >0–≤5 cm, moderate events measured >5–≤10 cm, and severe events measured >10 cm. Abbreviations: AE, adverse event; PCV13, 13-valent pneumococcal conjugate vaccine; V114, 15-valent pneumococcal conjugate vaccine.

Article Snippet: V114 (VAXNEUVANCETM, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA [MSD]) is a 15-valent PCV that contains the 13 serotypes in PCV13 plus two epidemiologically important serotypes (22F and 33F) that cause IPD [ , , , , , , , ].

Techniques: Injection

Journal: Vaccines

Article Title: Randomized Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of V114, a 15-Valent PCV, Followed by PPSV23 6 Months Later (PNEU-DAY): Subgroup Analysis in Adults 18–49 Years of Age Enrolled at Center for Indigenous Health Sites

doi: 10.3390/vaccines14010003

Figure Lengend Snippet: Serotype-specific OPA GMTs by timepoint and study group. Data are for participants enrolled at Center for Indigenous Health sites. The within-group 95% CIs were obtained by exponentiating the CIs of the mean of the natural log values based on the t-distribution. a Additional serotypes in V114. Abbreviations: CI, confidence interval; GMT, geometric mean titer (1/dilution); OPA, opsonophagocytic activity; PCV13, 13-valent pneumococcal conjugate vaccine; V114, 15-valent pneumococcal conjugate vaccine.

Article Snippet: V114 (VAXNEUVANCETM, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA [MSD]) is a 15-valent PCV that contains the 13 serotypes in PCV13 plus two epidemiologically important serotypes (22F and 33F) that cause IPD [ , , , , , , , ].

Techniques: Activity Assay

Journal: Vaccines

Article Title: Randomized Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of V114, a 15-Valent PCV, Followed by PPSV23 6 Months Later (PNEU-DAY): Subgroup Analysis in Adults 18–49 Years of Age Enrolled at Center for Indigenous Health Sites

doi: 10.3390/vaccines14010003

Figure Lengend Snippet: Serotype-specific OPA GMTs at 30 days post-vaccination (Day 30) with V114, by age. Data are for participants enrolled at Center for Indigenous Health sites. The within-group 95% CIs were obtained by exponentiating the CIs of the mean of the natural log values based on the t-distribution. a Additional serotypes in V114. Abbreviations: CI, confidence interval; GMT, geometric mean titer (1/dilution); OPA, opsonophagocytic activity; V114, 15-valent pneumococcal conjugate vaccine.

Article Snippet: V114 (VAXNEUVANCETM, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA [MSD]) is a 15-valent PCV that contains the 13 serotypes in PCV13 plus two epidemiologically important serotypes (22F and 33F) that cause IPD [ , , , , , , , ].

Techniques: Activity Assay

Journal: Vaccines

Article Title: Randomized Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of V114, a 15-Valent PCV, Followed by PPSV23 6 Months Later (PNEU-DAY): Subgroup Analysis in Adults 18–49 Years of Age Enrolled at Center for Indigenous Health Sites

doi: 10.3390/vaccines14010003

Figure Lengend Snippet: Serotype-specific OPA GMTs before and 30 days after PPSV23 vaccination. Data are for participants enrolled at Center for Indigenous Health sites. The within-group 95% CIs were obtained by exponentiating the CIs of the mean of the natural log values based on the t-distribution. a Additional serotypes in V114. Abbreviations: CI, confidence interval; GMT, geometric mean titer (1/dilution); OPA, opsonophagocytic activity; PCV13, 13-valent pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal polysaccharide vaccine; V114, 15-valent pneumococcal conjugate vaccine.

Article Snippet: V114 (VAXNEUVANCETM, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA [MSD]) is a 15-valent PCV that contains the 13 serotypes in PCV13 plus two epidemiologically important serotypes (22F and 33F) that cause IPD [ , , , , , , , ].

Techniques: Activity Assay